Sangamo Therapeutics

Sangamo signs licensing agreement with Genentech worth up to $1.9 billion

08-Aug-2024 By Clara Rodriguez Fernandez

The agreement will give Genentech access to Sangamo’s capsid delivery platform and epigenetic regulation technology with applications in neurodegenerative disease.

Novartis and Biogen exit deals with Sangamo

21-Mar-2023 By Jane Byrne

Both Novartis and Biogen have terminated partnerships with Sangamo Therapeutics in the past week.

SVB collapse: As biotechs report exposure to lender, US government moves to guarantee deposits and HSBC buys UK unit

13-Mar-2023 By Jane Byrne

Businesses and individuals that have money deposited with failed US bank Silicon Valley Bank (SVB) will be able to access all their cash from today, said the US government.

Sangamo and Novartis partner on gene therapies for autism

03-Aug-2020 By Ben Hargreaves

The two companies will develop three neurodevelopmental targets, using the former’s zinc-finger technology.

Mogrify and Sangamo in license agreement for ‘off-the-shelf’ CAR-Treg

23-Apr-2020 By Ben Hargreaves

Sangamo plans to utilize Mogrify’s cell conversion technology to develop CAR-Treg cell therapies.

Biogen dives deeper into Alzheimer’s with $350m deal

04-Mar-2020 By Ben Hargreaves

Biogen signs a partnership agreement with Sangamo for the use of zinc-finger technology to progress various neurological disease candidates.

TxCell CEO says acquisition by Sangamo a ‘perfect fit’

25-Jul-2018 By Ben Hargreaves

TxCell confirmed that it has accepted a €72m offer from Sangamo in a deal that will be completed by the end of the year.